share_log

Insider Spends US$3.0m Buying More Shares In Inari Medical

Insider Spends US$3.0m Buying More Shares In Inari Medical

內幕人士花費300萬美元購買更多Inari Medical股份
Simply Wall St ·  2023/11/11 07:11

Those following along with Inari Medical, Inc. (NASDAQ:NARI) will no doubt be intrigued by the recent purchase of shares by Donald Milder, Independent Chair of the Board of the company, who spent a stonking US$3.0m on stock at an average price of US$53.44. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 1.7%.

毫無疑問,跟隨Inari Medical, Inc.(納斯達克股票代碼:NARI)的人會對該公司董事會獨立主席唐納德·米爾德最近收購股票感興趣,他在股票上花費了驚人的300萬美元,平均價格爲53.44美元。不可否認,如此大規模的買入表明他們對更光明的未來充滿信心,儘管我們確實注意到,按比例計算,這隻會使他們的持股量增加了1.7%。

View our latest analysis for Inari Medical

查看我們對 Inari Medical 的最新分析

Inari Medical Insider Transactions Over The Last Year

去年的Inari Medical內幕交易

In the last twelve months, the biggest single sale by an insider was when the Director, William Hoffman, sold US$5.7m worth of shares at a price of US$70.87 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$53.27. So it may not tell us anything about how insiders feel about the current share price.

在過去的十二個月中,內部人士最大的一次出售是董事威廉·霍夫曼以每股70.87美元的價格出售了價值570萬美元的股票。雖然我們通常不喜歡看到內幕銷售,但更令人擔憂的是是否以較低的價格進行銷售。令人欣慰的是,此次出售的價格遠高於當前的股價,即53.27美元。因此,它可能無法告訴我們內部人士對當前股價的看法。

All up, insiders sold more shares in Inari Medical than they bought, over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

總而言之,去年業內人士出售的Inari Medical股票多於他們購買的股份。您可以在下表中看到過去一年的內幕交易(由公司和個人進行的)。點擊下圖,你可以看到每筆內幕交易的確切細節!

insider-trading-volume
NasdaqGS:NARI Insider Trading Volume November 11th 2023
納斯達克GS:NARI 內幕交易量 2023 年 11 月 11 日

I will like Inari Medical better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些重大的內幕收購,我會更喜歡Inari Medical。在我們等待的同時,請查看這份免費清單,列出了最近有大量內幕收購的成長型公司。

Does Inari Medical Boast High Insider Ownership?

Inari Medical 是否擁有很高的內部所有權?

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Inari Medical insiders own 9.9% of the company, currently worth about US$308m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。我們通常希望看到相當高的內部所有權水平。稻荷醫療內部人士擁有該公司9.9%的股份,根據最近的股價,目前價值約3.08億美元。大多數股東會很高興看到這種內部所有權,因爲這表明管理層的激勵措施與其他股東非常一致。

So What Do The Inari Medical Insider Transactions Indicate?

那麼,Inari Medical Insider 交易表明了什麼?

Unfortunately, there has been more insider selling of Inari Medical stock, than buying, in the last three months. And our longer term analysis of insider transactions didn't bring confidence, either. It is good to see high insider ownership, but the insider selling leaves us cautious. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 2 warning signs for Inari Medical you should know about.

不幸的是,在過去的三個月中,Inari Medical股票的內幕拋售多於買入的股票。而且,我們對內幕交易的長期分析也沒有帶來信心。看到較高的內部所有權是件好事,但內幕拋售使我們持謹慎態度。雖然我們喜歡了解內部人士的所有權和交易情況,但在做出任何投資決策之前,我們一定要考慮股票面臨的風險。每家公司都有風險,我們發現了兩個你應該知道的Inari Medical警告信號。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論